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COUGH AEROSOL PRODUCTION IN PATIENTS WITH PULMONARY  
 
TUBERCULOSIS WITH AND WITHOUT HIV INFECTION 	
SARA SAYED TALIB OSMAN 
 
ABSTRACT 
 
Rationale:  Infectivity of patients with pulmonary tuberculosis who are HIV infected is 
not clear compared to those who are non-HIV infected.  There is an association between 
cough aerosol production and T.B transmission with great variability in the amount of 
aerosol produced by infected patients; therefore aerosol production can be used as 
surrogate marker of infectivity  
Objectives: To evaluate the amount of cough aerosol produced in patients with 
pulmonary tuberculosis who are HIV infected compared to those who are non-HIV 
infected; and to evaluate the association between immunosuppression and aerosol 
production.  
Methods: Data from two different cohorts with available information on the amount of 
cough aerosol produced and HIV status were merged to increase validity of the study  
Measurements and main results: Secondary data analysis performed on the merged 
data using the amount of mycobacterial tuberculosis colony forming unit produced in 
cough aerosol by patients with pulmonary tuberculosis as our outcome variable and 
compared HIV infected patients with non-HIV infected; thereafter in the HIV-subgroup 
we ran data analysis to evaluate the association between aerosol production and degree T-
cell count.  
		 v 
Conclusion: HIV infection is associated with decrease aerosol production in patients 
with pulmonary tuberculosis, other factor included degree of AFB smear the duration on 
TB treatment before aerosol collection modified this association. In HIV infected person 
the degree of immunosuppression dose not correlate with the amount of aerosol 
produced.  			 	
		 vi 
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I: Summary: 
 
Tuberculosis (TB) remains a global health problem. It is the leading cause of death in 
people living with HIV. The cycle of the disease begins when a human host inhales 
aerosols containing viable Mycobacterium tuberculosis (MTB).  To date, studies looking 
at the effect of HIV immunosuppression on infectivity of patients with pulmonary TB 
have produced inconclusive results (1–3). Jones-Lopez et al. (4) have established a strong 
association between the number of colony forming units (CFU) of MTB in cough-
generated aerosol in patients with pulmonary TB and risk of infection in exposed 
contacts. There have been no studies looking at amount of culturable MTB in cough 
aerosol of patients co-infected with HIV and TB.  
 
Secondary analysis of currently available data from studies with baseline assessment of 
cough aerosol cultures of MTB can provide very useful information to assess a potential 
link between HIV status and TB infectivity. Our objective is therefore to investigate the 
association between HIV status and the amount of culturable MTB produced in cough 
aerosol of patients with pulmonary TB as a surrogate marker of infectiousness using 
available data from two prospective studies (4,5). 		
II: Background: 
 
Tuberculosis remains a global health problem. It is ranked as the second leading cause of 
death from a single infection after HIV.  In its latest global report, the World Health 
Organization (WHO) estimated over 9.6 million people fell ill with TB in 2014 (6); of 
those an estimated 12% million were HIV infected. About 1.4 million people died of the 
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disease in 2014; of those 320,000 were HIV infected. Globally, approximately one third 
of HIV infected individuals have latent TB infection (LTBI). It is known that patients 
with HIV are 29.6 times more likely to develop active disease compared to non-HIV 
infected individuals (6).   
 
Multidrug-resistant (MDR) TB, defined by antituberculous drug resistance to at least 
isoniazid and rifampicin, is an increasingly important public health and clinical issue, 
especially in countries with a high burden of HIV. In March 2006, the first data were 
published on the worldwide occurrence of TB with resistance to second-line drugs (7), 
termed extensively drug-resistant (XDR) TB and defined as resistance to isoniazid, 
rifampicin, any fluoroquinolone, and at least one of three injectable second-line drugs. In 
2011 WHO published in it’s MDR-TB & XDR-TB progress report that 69 countries have 
reported at least one case of XDR-TB (by the end of 2010), and currently there are an 
estimated 25,000 cases of XDR-TB emerging every year (8). Studies from New York and 
South Africa have shown increased mortality and shorter median survival among HIV-
infected MDR-TB patients compared to those without HIV infection. A report from 
KwaZulu-Natal Province, South Africa indicated that 52 out of 53 patients with XDR-TB 
were HIV positive, and had a median survival time of only 16 days from sputum 
collection, and a 98% mortality rate (7).  	
It is well known that MTB is transmitted by fine aerosols (i.e. via the airborne route in 
infectious droplet nuclei < 5 mm in diameter). Recent studies have shown (4,5,9) 
significant variability in the amount of culturable MTB in cough aerosol of patients with 
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pulmonary TB, and MTB CFU has been shown to correlate with both tuberculin skin test 
(TST) and interferon gamma release assay (IGRA) conversion in close contacts of an 
index case. While sputum acid fast bacilli (AFB) has been the gold standard for 
predicting infectivity for decades, these findings suggest that the amount of MTB CFU in 
cough aerosol could be used as a surrogate marker for transmission and infectivity.    
 
There are several reasons why HIV infected patients with pulmonary TB may be less 
likely to transmit TB infection when compared to HIV-uninfected patients including that 
HIV infected patients are more likely to be sputum AFB negative, have fewer cavitary 
lesions, and have a reduced period of infectiousness since they progress from infection to 
death more quickly.  
 	
III: Study questions: 
 
1- Is there an association between HIV infection and cough aerosol producon in patients 
who have pulmonary tuberculosis? 
 
2- Among HIV-infected persons, is there an association between degree of 
immunosuppression, as measured by CD4 cell count, and cough aerosol production? 
 
 
IV: Study Objectives and Hypotheses: 
 
Objectives:  
1. Examine the effect of HIV on the amount of MTB CFU produced in cough-generated 
aerosol of patients with pulmonary TB. 
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2. Evaluate the association between degree of immunosuppression and aerosol production 
in HIV-infected patients who are co-infected with pulmonary TB. 		
Hypothesis I:  
Individuals with HIV-associated pulmonary TB will produce lower number of MTB CFU 
in their aerosol compared to HIV-uninfected individuals.  
 
Hypothesis II:  
HIV-infected patients with CD4 ≥200 or no AIDS clinical diagnosis will produce higher 
aerosol CFU compared to those with CD4< 200 or AIDS clinical diagnosis.  
 
The cut-off of 200 cells was chosen based on CDC definition of AIDS. This category also 
included all persons with a diagnosis of opportunistic infection or AIDS defining 
condition.  
 
V: Methods:  
 
q Study Design: A cross sectional study analyzed data from two cohorts with 
available cough aerosol information (N=185); (2002–2004, 2009–2011) 	
q Settings/Study population:  Two studies were combined for this secondary data 
analysis. Our data analysis was restricted to patients with sputum culture positive 
confirmed pulmonary TB with available cough aerosols data and HIV status 
information. The two studies used different sputum AFB smear grading; in our 
secondary analysis we will be using the WHO grading system (0 or Negative, 1+, 
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2+, 3+, 4+). 
  
§ Both studies included patients with pulmonary tuberculosis, attending the 
Mulago Hospital in Kampala, Uganda 
§ Both studies included subjects only if their sputum was confirmed to be 
culture-positive for MTB  
§ Cough Aerosol Sampling System (CASS) was used to collect, quantify, 
and size aerosol particles containing culturable MTB produced by 
voluntary coughing in patients with active pulmonary TB in both cohorts.  	
q Parent studies: 
 
Study 1  
A prospective cohort designed to study nosocomial TB transmission and to evaluate the 
feasibility of collecting cough aerosols in a resource-limited setting in Kampala, Uganda. 
 
• From 11/2002 to 12/2004, consecutive patients with suspected TB attending the 
National Tuberculosis and Leprosy Program Chemotherapy Centre at Mulago 
Hospital in Kampala, Uganda were enrolled. 
• Subjects were included if their sputum was confirmed to be culture-positive for 
MTB 
• Study excluded patients with medical conditions that could be worsened by cough 
or if they were too ill to consent, or unable to understand or to comply with the 
protocol	
• Sputum AFB graded using WHO criteria (0 or negative, 1+, 2+, 3+, 4+) 
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• 112 patients had suspected TB; 101 (90%) had confirmed culture-positive 
sputum.  
• Included patients who were retreatment TB and patients with MDR-TB 
• Patients were mainly inpatient, sick, older in age, with higher HIV-infection rate. 
• Of the 112 patients with suspected TB enrolled only 92 had all AFB smear, 
culture and HIV data and included in our final merged data for analysis.  		
Study 2  
A prospective household contact study designed to evaluate the use of cough-generated 
aerosols of MTB to predict recent transmission within households. 
 
• From 5/2009 to 1/2011, patients with pulmonary TB attending the Mulago 
Hospital National Tuberculosis and Leprosy Program (NTLP) clinic in Kampala, 
Uganda, and their household contacts were enrolled.  
• Included patients who were 18 years or older, had a new TB episode with at least 
one sputum specimen that was initially AFB greater than or equal to 1+ with 
subsequent growth of M. tuberculosis in culture and were untreated or had 
received 5 days or less of TB treatment, this study also included contacts of the 
index case. 
• Study excluded patients with medical conditions that could be worsened by cough 
or if they were too ill to consent, or unable to understand or to comply with the 
protocol. 
• Sputum AFB was graded using CDC/ATS grading criteria (Negative, Scanty, 1+, 
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2+, 3+) (Table 1) 
• Patients were mainly outpatients, young, healthy with low HIV infection rate.  
• This study included 96 index TB cases of those we excluded 3 patients in our 
final data merged due to missing HIV data. 	
Table 1. ATS and IUATLD sputum AFB smear grading 
 
ATS 
Classification 
IUATLD * 
Classification  
Acid Fast Bacilli 
Negative 0 (negative) 0 AFB/100 fields 
scanty 1+ 1–9 AFB/100 fields 
1+ 2+ 1–9 AFB/10 fields 
2+ 3+ 1–10 AFB/field 
3+ 4+ >10 AFB/field 
       *Classification used in our data analysis 
 
 
VI: CASS Method  
CASS consists of a custom-built stainless steel cylindrical chamber with non-
compressible tubing connecting the inlet to a disposable mouthpiece. The chamber holds 
two Andersen six-stage cascade impactors for viable bioaerosol sampling, each with six 
plastic Petri plates holding selective 7H11 agar that were loaded in a class II biological 
safety cabinet.  
 
A vacuum pump connects the air samplers by tubing to fittings that pass through the wall 
of the chamber. In-line 47-mm filter holders loaded with high-efficiency particle air 
filters are placed between the chamber and the vacuum pump for biosafety.  
 
A single-stage impactor loaded with the same 7H11 agar was used to sample ambient 
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room air. One settle plate of the same agar was placed inside the chamber and one in the 
study room to sample large aerosol particles. A timer connected to the vacuum pump was 
set for 5 minutes.  
 
Subjects were instructed to cough into the CASS mouth- piece as much and as frequently 
as was comfortable for two 5-minute sessions separated by a rest of approximately 5 
minutes. No sputum induction was used.  
 
After collection, the aerosol samplers were removed and transported to the laboratory, 
where they were unloaded in the biological safety cabinet. Plates were incubated at 370C.  
 
Cultures were read at 1 week to detect any rapidly growing contaminants and then at 3, 6, 
and 9 weeks to record CFU of M. tuberculosis  
 
Cut off of >10 CFU will be used in the analysis to evaluate for risk factors association 
between MTB aerosol production. This cut off was used based on studies showing an 
association between high MTB aerosol (CFU>10) and TST in close contacts (11).  
 
 
VII: Statistical Methods 
 
Data has been collected using Microsoft Office Access 2011 and Microsoft Excel. Data 
was analyzed using Statistical Analysis Software (SAS) version 9.4.  
 
Data is being presented graphically using boxplots for continuous data and frequency 
histogram for categorical data.   
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The primary outcome of interest was log CFU in cough aerosol was measured as a 
continuous variable (Figure 1), the primary predictor of interest was HIV status in the 
whole sample and CD4 cell count in HIV infected subset of patients; both were 
dichotomized. 
 
Demographic characteristics of the two cohorts were compared reporting on mean, 
standard deviation, median and interquartile range [IQR] for continuous variables and 
frequency and percent for categorical variables. Variables were compared between the 
two cohort for statistically significant difference at the level of 0.05.    
 
First, we ran a crude analysis to evaluate the relation between the exposure (HIV status in 
index TB cases) and the outcome of interest (number of CFU of MTB in cough-generated 
aerosols) at the univariate level. We also examined the association with other factors 
(Epidemiological, historical risk factors for TB) and amount of aerosol CFU all at the 
univariate level using a simple logistic regression reporting the regression coefficient for 
each variable, t-test along with the P-value associated with it.  
 
We then used a multiple logistic regression model to fit all variables that may be 
associated with aerosol production based on the results of the univariate analysis and 
literature review for historical variables that have been associated with increased risk of 
transmission of the infection. In order to evaluate for potential confounding we examined 
the effect of each variable in the crude estimate of association between the main predictor 
of interest and our outcome, comparing the adjusted estimate of association.  If the 
adjusted estimate differs from the crude by more than 10%, we then retained that variable 
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for inclusion in our final multivariable model. After having evaluated all potential 
confounders in this fashion, we built a comprehensive multivariable model.  
 
Also, we also examined effect modification through stratified analyses and by including 
interaction terms in our analytic models. Potential effect modifiers were identified on a 
prior basis based on biologic or clinical theory or evidence from the literature. We will 
present and report on all the interactions. Results will be presented using unadjusted and 
adjusted regression coefficient with the associated P-value and T-value where applicable.  
 
 
Outcome and Measurements 
q Demographic 
• Age 
• Sex 
q Clinical 
• BMI 
• HIV status 
• TB status 
• Duration of TB symptoms 
• Days on TB treatment before enrollment 
• Chest Imaging  
q Laboratory  
• CD4 cell count 
• Sputum AFB & culture (MGIT) 
• Days to culture positivity  
• Aerosol’s Colony Forming Units (7H10 Middlebrook agar) 
 
 
VIII: Results:  
 
Our secondary data analysis included a total of 185 patients; data were generated by 
combining data from two different prospective studies of patients with sputum culture 
positive confirmed pulmonary tuberculosis.  
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Table 2 shows the basic demographic characteristics of our study subjects stratified by 
cohort data indicating variables that are significantly different between the two cohorts at 
the level of 0.05.  
 
On comparing demographic characteristics between the two studies we found while 
participants in the first study were older than those in the second cohort, this was not 
significant. However, there were more males in the first study compared to the second 
study. HIV infection status was significantly different between the two cohorts as well as 
TB-Status, with more retreatment cases coming from the first cohort, the first cohort were 
on TB treatment for significantly longer duration compared to the second cohort.  
Participants in the first study also had significantly lower BMI compared to the second 
cohort; however disease severity as measured by extent of lung disease and presence of 
cavitation did not differ between the two cohorts. Figure 1 shows the normal histogram 
for the distribution of Log Aerosol for the merged data.  
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Table 2. Basic characteristics of study subjects 
 
Variable 
Median [IQR] 
Frequency (%) 
Cohort 1 
(2002–2004) 
N= 92 
Cohort 2  
(2009–2011) 
N= 93 
Total 
N= 185 
Demographic  
Age  30 [28, 38] 29 [24, 40] 30 [25, 39] 
Sex* 
    Male 
    Female 
  
62 (67) 
30 (33) 
  
47 (51) 
46 (49) 
  
109 (59) 
76 (41) 
BMI* 17 [16, 19] 19 [18, 21] 18 [17, 20] 
HIV* 
    Positive  
    Negative 
  
56 (61) 
36 (39) 
  
21 (23) 
72 (77) 
  
77 (42) 
108 (58) 
CD4  
    Absolute 
  
121 [33, 281] 
  
264.5 [142, 320] 
  
140 [44, 312] 
CD4* 
    ≥200 
    <200 
    Missing 
  
18 (32) 
36 (64) 
2 (4) 
  
7 (33) 
3 (14) 
11 (53) 
  
25 (32) 
39 (51) 
13 (17) 
Clinical  
TB Status* 
    New 
    Retreatment 
  
23 (25) 
69 (75) 
  
93 (100) 
0 (0) 
  
116 (63) 
69 (37) 
Duration of TB 
symptoms in weeks 
12 [7, 20]  12 [8, 16] 12 [8, 18] 
Duration of TB 
treatment* 
4 [3, 6] 1 [1, 2] 3 [2, 5] 
Aerosol CFU* 
     Median [IQR] 
     Mean (sd) 
     Range 
  
0 [0, 1]  
3.91 (10.16) 
0–59 
  
0 [0, 10] 
16.4 (49.5) 
0–378 
  
0 [0, 4] 
10.19 (36.24) 
0–378 
CXR findings  
Cavitary Disease 
    Present 
    Absent 
    Missing 
  
53 (58) 
34 (37) 
5 (5) 
  
60 (65) 
28 (30) 
5 (5) 
  
113 (65) 
50 (29) 
10 (6) 
Extent of disease on 
CXR 
     Far advanced 
     Other 
     Missing 
  
74 (80) 
13 (14) 
5 (6) 
  
80 (86) 
8 (9) 
5 (5) 
  
154 (88) 
21 (12) 
10 (6) 
Sputum and Culture data  
Sputum Smear* 
    Positive 
    Negative 
  
77 (84) 
15 (16) 
  
92 (99) 
1 (1) 
  
169 (91) 
16 (9) 
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Variable 
Median [IQR] 
Frequency (%) 
Cohort 1 
(2002–2004) 
N= 92 
Cohort 2  
(2009–2011) 
N= 93 
Total 
N= 185 
AFB Smear* 
       0(Negative) 
       1+ 
       2+ 
       3+ 
       4+ 
  
 15 (16) 
6 (7) 
10 (11) 
24 (26) 
37 (40) 
  
 0 (0) 
1 (1) 
13 (14) 
13 (14) 
66 (71) 
  
 15 (8) 
7 (4) 
23 (12) 
37 (20) 
103 (6) 
Days to positive cx*  8 [4, 13] 6 [4, 8] 6 [4, 10] 
Sputum Culture 
     0 
     <20 
     20–100 
     100–200 
     >200 
  
12 (16) 
0 (0) 
4 (4) 
2 (2) 
72 (78) 
  
4 (4) 
1 (1) 
4 (4) 
3 (3) 
81 (87) 
  
16 (9) 
1 (1) 
8 (4) 
5 (3) 
153 (83) 
*Variables that are significantly different between the two cohorts at p=0.05 
 
 
 
 
 
 
 
 
Figure 1. Normal histograms of Log Aerosol  
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Results – Objective 1: The effect of HIV infection on MTB CFU on cough aerosol of 
co-infected patients 
 
On a univariate analysis to examine the association between our predictor variables and 
log aerosol using a simple linear regression; we found that HIV status and AFB smear 
grade were both significantly associated with aerosol production at the level of 
significance of 0.05, but no other factors were found to be associated with aerosol 
production (Table 3, Figures 2 & 3) 
 
We then started building our final model to include all predictors of aserosol production 
and examine for presence of confounders and effect modifiers; we first chose variables to 
be tested for inclusion in our final model (Table 3), variables were chosen based on their 
effect on the aerosol production at the univariate level, we also tested for 
epidemiologically important variables and variables from literature review has been 
historically associated with TB transmission; we used a 10% change in the adjusted 
regression coefficient of HIV from the crude regression coefficient as our criterion to 
retain the variable in our final model; testing one variable at a time and calculating 
percent change in the crude regression coefficient using the formula % Change=   βcrude  
- βadjusted / βadjusted (Tables A1–A8 in addendum), we retained in our final model those 
variables that changed the crude association between HIV status and aerosol production 
by 10% or more. Our final model included HIV status, Duration on TB treatment, and 
AFB Smear Grade (Table 4); AFB smear grading decreased the regression coefficient of 
HIV status by 21% (adjusted regression coefficient=0.7338 down from 0.9795) but HIV 
status remained significantly associated with aerosol production (P=0.048), when we 
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added duration on TB treatment to the model after retaining AFB smear grading the 
regression coefficient of HIV increased by 14%(regression coefficient= 1.033, P=0.084) 
Although the P-Value for the effect of HIV on aerosol production is not statistically 
significant in our final model this can be explained by that duration of TB treatment 
before aerosol collection is an effect modifier as its known from previous studies that TB 
treatment reverse AFB smear positivity and decrease aerosol production (11)When 
testing for interaction between HIV infection and duration on TB treatment we found 
none between the two variables that affect the regression coefficient significantly (not 
reported), we also found no interaction between AFB smear grading and duration on TB 
treatment, this indicates that duration on TB treatment is not a confounder and is an effect 
modifier.   
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Table 3:  The univariate analysis for variables associated with aerosol production  
 
Variable Regression  
Coefficient  
t test P-value 
Age -0.0015 -0.09 0.932 
Sex 
    Male 
    Female 
 
ref. 
-0.0679 
- 
-0.18 
0.860 
BMI 0.1075 1.57 0.122 
HIV  
     Positive 
     Negative 
 
ref. 
0.8843 
- 
2.42 
0.018* 
TB Status 
     New 
     Retreatment  
 
ref.  
0.1925 
- 
0.45 
0.610 
Cavitary lung disease 
    Absent 
    Present 
 
ref. 
-0.0451 
 
- 
-0.11 
0.909 
Log Days to culture positivity  -0.3912 -1.40 0.167 
Log Duration of TB symptoms 0.0613 0.22 0.828 
Duration on TB treatment 0.0289 1.37 1.80 
AFB smear grade 
     0/1+/2+ 
     3+ 
     4+ 
  
ref. 
-0.1182 
1.0892 
 
- 
-0.17 
2.11 
 
- 
0.869 
0.038* 
Cohort data 
    Cohort 1 
    Cohort 2 
  
-0.0741 
ref. 
-0.19 
  
0.853 
  
* P-value significant at the level of 0.05 
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Figure 2: The association between HIV and aerosol production  
 
 
 
Table 4. The final models for factors associated with aerosol production 
 
Independent 
Variable  
Regression  
Coefficient  
t- test  P-value  
HIV 
Negative 
Positive 
 
1.033 
ref. 
1.79 0.084 
Sputum Smear Grade 
3+ 
4+ 
0/1+/2+ 
 
0.567 
1.027 
ref. 
 
0.70 
1.69 
 
0.491 
0.103 
Days on TB treatment  0.267 1.32 0.198 
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Results – Objective 2:  The correlation between degree of immunosuppression and 
aerosol production in HIV co-infected patients 
 
We subset our data set to include HIV infected individuals only (N=64) to examine the 
effect of degree of immunosuppression on aerosol production. Table A9 (addendum) 
shows the basic demographic information of these participants. There were more males 
who were HIV-infected than females. The median CD4 count was 140 with an IQR of 44 
& 312.  
 
On this subset of data, we found that log aerosol is normally distributed which allows for 
analyzing the outcome as a continuous variable (Figure A 11 addendum).  However, CD4 
count was not normally distributed so will be dichotomized using a cut off 200, which 
aligns with the CDC definition of AIDS (Figure A12 addendum).  
 
In a univariate analysis we found that TB treatment status and AFB smear grade was 
associated with aerosol production in HIV infected patients (Table A10 addendum) while 
the degree of immunosuppression measured by CD4 count was not associated with 
aerosol production (Table A10 addendum & Figure 3). 
 
Given that regression coefficient for the association between CD4 cell count and log 
aerosol production was small and to avoid overestimation of the effect of a variable 
(adjusted regression coefficient) on the relationship between CD4 count and log aerosol 
production; we first ranked all variables based on the their absolute effect on the 
regression coefficient of CD4 cell count (Table A11 addendum). 
 
We then started building our final model including variables for analysis based on their 
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ranking. Variables were retained in our final model based on the 10% rule of change in 
the crude measure of association between our main predictor (CD4 count) and our 
outcome of interest; Log aerosol production (Tables A12–A18 addendum); we also 
forced variables that were significant at the univariate level in our final model (Table A19 
addendum). 
 
Our final model included CD4 cell count, age, cavitary lung disease, sex, duration of TB 
symptoms, TB treatment status, Duration on TB treatment and AFB smear grade. We 
also ran a separate model that included only our main predictor of interest (CD4 count) 
and the variables that was significant at the univariate level (AFB smear grade and TB 
treatment status) (Table 5). The results were not different from the original final model. 
To examine if there is any masked associated between CD4 count and aerosol production 
we ran a simple linear regression examining the relation between CD4 count and log 
aerosol and found no association  
Table 5: The final model for predictors of aerosol production in HIV infected 
patients  
 
Independent 
variable 
Regression 
coefficient 
t-test P-value 
CD4 count 
≥200 
<200 
 
-0.1279 
ref. 
-0.23 0.819 
Independent variable Regression coefficient t-test P-value 
TB Status * 
Retreatment 
New 
 
0.9747 
ref. 
1.73 0.106 
Smear category * 
0/1+/2+ 
3+ 
4+ 
 
ref. 
1.0685 
1.4824 
 
- 
1.23 
1.94 
0.238 
0.072 
*Variables that are associated with aerosol production at p=0.05 in univariate analysis 
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Figure 3: Boxplot of aerosols distribution based on CD4 category   
 
 
Results – Conclusion: 
In our secondary data analysis we found that HIV infection status is associated with the 
amount of MTB CFU produced in cough aerosol in patients who are co-infected with 
pulmonary tuberculosis; HIV-uninfected subjects produced more CFU in their cough 
aerosol compared to HIV infected individuals (regression coefficient= 0.8843, t=2.42, 
P=0.018), another factor that is associated with the amount of CFU in aerosol is AFB 
smear grading; individuals with AFB smear grade 4+ produced more MTB CFU in their 
cough aerosol compared to those grade 0–2+(regression coefficient= 1.089, t=2.11, 
P=0.038). On examining for confounders and the effect modification of other variables 
on the association between HIV infection status and aerosol production we found that 
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duration on TB treatment before aerosol collection modified the effect of HIV on the 
amount of TB CFU on cough aerosol (% change in regression coefficient 12); this effect 
modification is expected since previous studies have shown strong association between 
TB treatment and reversal of aerosol production regardless of HIV infection status.  
 
In the HIV infected subset of subjects the degree of immunosuppression as measured by 
CD4 count and presence of AIDS defining illness was not associated with aerosol 
production in patients who are co-infected with pulmonary TB.  
 
IX: Strengths and Limitations 
 
Weaknesses/Limitations: 
 
First, this is an observational study and, thus, is susceptible to confounding influences 
that hinder causal inference. Second, although we found that HIV seropositive 
individuals who are co-infected pulmonary TB are likely less infective to their close 
contacts compared to HIV seronegative individuals with pulmonary TB, this study was 
not designed to directly measure transmission, therefore direct correlation cannot be 
assumed. However, we think from prior studies that the amount of CFU in cough aerosol 
could be a good surrogate marker of infectivity. Third, the effect of HIV treatment on the 
amount of MTB CFU in cough aerosol was not measured and the rate at which patients 
alter their cough aerosol status or CD4 count in response to start of HIV treatment is 
unknown.  
 
In our analysis we combined data from two different cohort studies with slightly different 
inclusion and exclusion criteria for each study and studies conducted at different times 
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and this may have affected our findings; however there was no correlation between 
cohort data and cough aerosol production in our analysis  
 
Missing CD4 cell count data in some of the HIV infected subjects may have affected our 
ability to detect an association between degree of immunosuppression and aerosol 
production.  
 
 
Strengths: 
 
This secondary data analysis has several notable strengths; To our knowledge, this study 
is the first to look at the association between HIV-status and the amount of MTB CFU 
produced on cough aerosol a surrogate marker of infectivity. 
 
By combining two data sets, this is largest study to date with aerosol data available in all 
subjects, which increased our power to detect differences between HIV-infected and 
HIV-uninfected patients; this may explain why our findings are different from Fennelly’s 
findings (4) 
 
Both studies were conducted at the same site and data collected included information on 
similar variables using the same methods for both studies, which increased the internal 
validity of our study.  
 
Careful consideration of clinical, radiologic and microbiologic confounders with 
relatively complete data allowed us to control for these. 
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X: Importance and Future Directions: 
 
This study assessed infectious M. tuberculosis aerosol produced by HIV-infected 
individuals as a surrogate marker of infectivity, and the results of our study could help 
resolve the question of differential infectiousness associated with HIV infection. This is 
an important question to answer in the era of increased MDR- and XDR-TB where our 
treatment options are limited.  
Since data suggest that only 25–45% of patients with pulmonary TB are infectious (10), 
improving assessment and identification of infectious individuals could have major 
implications for infection control, especially in resource-limited areas where TB and HIV 
are highly endemic; and where HIV complicates these measures (11–13).  
The findings from this study could allow for more cost-effective resource allocation and 
targeted contact tracing and investigations in the community. Most importantly, efficient 
identification of the most infectious individuals would help break the cycle of 
transmission and limit incidence of new cases moving us toward the goal of TB 
elimination and future studies should focus on identification of the most infectious 
individuals using a CASS technique.   
To move this into public health practice we need a more rapid and convenient technique 
to measure the amount of MTB CFU in cough generated aerosol, and future study should 
focus on improving aerosol-sampling systems.  
 
 
		
24 
XI: Role in the study:  
The investigator conducted data management and analysis. I wrote and reported the 
results of the study in this written thesis. I presented the results orally to the thesis 
committee.  
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Addendum 
 
Figures A1–A5: The distribution of all continuous variables in the data  
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The distribution of duration on TB treatment  
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Results for Objective 1: The effect of HIV infection on MTB CFU on cough aerosol 
of co-infected patients 
 
Variables that were be tested for inclusion 
 
q Main predictor of interest  
• HIV 
q Epidemiologically significant variables  
• Age 
• Sex 
q Historically associated with transmission 
• Cavitary lung disease 
• Duration of TB symptoms 
• AFB smear grading  
q Statistically significant variable 
• Any variable was associated with aerosol production in the 
univariate analysis 
q Others 
• Days to culture positivity  
 
 
Building the Model (Tables A1–10)  
 
 
Table A1.  Simple linear regression between outcome and main variable of interest  
Independent 
Variable  
Regression  
Coefficient  
F-Model  t-test P-value comment 
Intercept  0.9795 5.84 1.61 1.61  
HIV Status 
    Negative 
    Positive 
  
0.8843 
ref. 
2.42 0.018* Main variable 
of interest 
 
Table A2. Adding Age to the model  
Independent 
Variable  
Regression  
Coefficient  
% Change  t-test  P-value Comment 
HIV Status 
    Negative 
    Positive 
  
0.9628 
ref. 
8.3 2.50 0.015* Main variable 
of interest 
Age 0.0126 - 0.67 0.503 Not retained 
in the model 
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Table A3. Adding Sex to the Model 
  
Independent 
Variable  
Regression  
Coefficient  
% Change  t-test  P-value Comment 
HIV Status 
    Negative 
    Positive 
  
0.9005 
ref. 
1.83 2.41 0.019* Main variable 
of interest 
Sex 
   Female 
   Male 
0.0922 
ref. 
- 0.25 0.807 Not retained 
in the Model  
 
 
Table A4. Adding Cavitary Lung Disease to the Model 
  
Independent 
Variable  
Regression  
Coefficient  
% Change  t-test  P-value Comment 
HIV Status 
    Negative 
    Positive 
  
0.8097 
ref 
-9.2 2.17 0.034* Main variable 
of interest 
Cavitary 
disease 
    Present 
    Absent  
-0.0126 
ref 
- -0.03 0.974 Not retained 
in the Model 
 
 
Table A5. Adding Days to Culture Positivity to the Model  
 
Independent 
Variable  
Regression  
Coefficient  
% Change  t-test  P-value Comment 
HIV Status 
    Negative 
    Positive 
  
0.8633 
ref 
-2.4 2.35 0.022* Main variable 
of interest 
Log DTP -0.3718 - -1.38 0.173 Not retained 
in the Model  
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Table A6. Adding Duration of TB symptoms 
 
Independent 
Variable  
Regression  
Coefficient  
% Change  t-test  P-value Comment 
HIV Status 
    Negative 
    Positive 
  
0.9626 
ref 
8.1 2.65 0.010* Main variable 
of interest 
Log Duration 
of symptoms  
-0.1397 - -0.05 0.959 Not retained 
in the Model  
 
 
Table A7. Adding AFB Smear Grading to the final model  
 
Independent 
Variable  
Regression  
Coefficient  
% Change  t-test  P-value Comment 
HIV Status 
    Negative 
    Positive 
  
0.7338 
ref 
-20.5 2.02 0.048* Main variable 
of interest 
AFB smear 
grade 
     0/1+/2+ 
     3+ 
     4+ 
ref 
0.0798 
1.0285 
- - 
0.11 
2.04 
- 
0.910 
0.046* 
Given % 
change of 
~21% which 
is more than 
10% we will 
retain AFB 
smear grade 
in our final 
Model 
 
 
Table A8. Adding Duration on TB treatment to the model  
 
Independent 
Variable  
Regression  
Coefficient  
% Change  t-test  P-value Comment 
HIV Status 
    Negative 
    Positive 
 
1.033 
ref. 
14% 1.79 0.084 Main variable 
of interest 
AFB smear 
grade 
     0/1+/2+ 
     3+ 
     4+ 
 
 
0.567 
1.027 
ref. 
- 0.70 
1.69 
0.491 
0.103 
Retain in the 
final model  
Duration on 
TB treatment 
0.267 - 1.32 0.198 Retain in the 
final model 
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Figures A6–A8: Boxplots of Log Aerosol in relation to categorical variables 
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Figures A9–A10: The relation between Log Aerosol and continuous variables  
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Objective 2:  The correlation between degree of immunosuppression and aerosol 
production in HIV co-infected patients 
 
 
Table A9. Basic demographic characteristics of HIV infected  
Variable  
N= 64 
Median [IQR] 
Frequency (%) 
 Age 35 [30, 40] 
Sex 
Male 
Female 
 
37 (58) 
27 (42) 
CD4  
≥200 
<200 
 
25 (39) 
39 (61) 
CD4  
Absolute 
Percent 
 
140 [44, 312] 
9 [4, 17] 
TB Status 
New 
Re-infected 
 
26 (41) 
38 (59) 
Cohort data 
Cohort 1 
Cohort 2 
 
54 (84) 
10 (42) 
Variable  
N= 64 
Median [IQR] 
Frequency (%) 
Sputum Smear 
Positive 
Negative 
 
54 (84) 
10 (16) 
Smear Grade 
0 
1+ 
2+ 
3+ 
4+ 
 
10 (16) 
3 (5) 
6 (9) 
18 (28) 
27 (42) 
Duration of TB treatment  3 [2, 5] 
Days to positive culture 2 [1, 3] 
Sputum Culture  
 0 
 <20 
              20–100 
             100–200 
              >200 
 
10 (16) 
0 (0) 
4 (6) 
3 (5) 
47 (73) 
Cavitary lung disease 
Present 
Absent  
Missing 
 
29 (45) 
33 (52) 
2 (3) 
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Figures A11–A12: The distribution of variables amongst HIV-infected individuals  
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Table A10. The univariate analysis of variables and association with aerosol 
production 
 
Variable Regression  
Coefficient  
     t test P-value 
CD4  
<200 
≥200      
 
-0.035 
ref. 
-0.06 0.955 
Age -0.004 -0.10 0.921 
Sex 
    Female 
    Male 
 
0.634 
- 
 
1.06 
- 
0.302 
TB Status* 
     Retreatment  
     New  
 
1.232 
ref. 
 
2.32 
- 
0.033* 
Cavitary lung disease 
    Present 
    Absent 
 
-0.529 
ref. 
 
-0.85 
- 
0.408 
Log Days to culture 
positivity  
-0.048 -0.13 0.812 
Duration of TB 
symptoms 
0.651 1.42 0.173 
AFB smear grade* 
     0/1+/2+ 
     3+ 
     4+ 
ref. 
0.879 
1.752 
- 
1.03 
2.31 
0.317 
0.035* 
Cohort data 
    Cohort 1 
    Cohort 2 
1.019 
ref. 
1.68 
  
0.110  
  
TBDUR 0.0299 1.50 0.154 
 
 
Tables: Building the Model  
 
Table A11. Ranking of variables based on their absolute effect on β CD4 
Variable β CD4 before adjustment 
(ref. CD4<200) 
β CD4 after adjustment 
(ref. CD4<200) 
1. Duration of TB symptoms -0.0353 0.3582 
2. Cavitary lung disease - 0.3508 
3. TB treatment duration - 0.3143 
4. Sex - 0.2149 
5.TB status - 0.0208 
6.Cohort data - 0.0818 
7.Sputum AFB smear - -0.1166 
8.Duration to positive culture - -0.0699 
9.Age - -0.0325 
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Table A12. Main variable of interest 
 
Independent 
variable 
Regression 
coefficient 
t-test P-value Comment 
CD4 count 
≥200 
<200 
 
-0.0353 
ref. 
-0.06 0.955 Main predictor of 
interest 
 
 
 
Table A13. Adding Duration of TB Symptoms   
 
Independent 
variable 
Regression 
coefficient 
% change t-test P-value Comment 
CD4 count 
≥200 
<200 
 
0.3582 
ref. 
110 0.55 0.589 Main predictor 
of interest 
Log duration of TB 
symptoms 
0.7648  - 1.5 0.154 Retain in the 
model 
 
 
 
Table A14. Adding Cavitary Lung Disease   
 
Independent 
variable 
Regression 
coefficient 
% change t-test P-value Comment 
CD4 count 
≥200 
<200 
0.4235 
ref. 
15 0.63 0.541 Main predictor 
of interest 
Log duration of TB 
symptoms 
0.2849  - 0.42 0.678 Retain in the 
model 
Cavitary lung 
disease 
Present  
Absent  
-0.5202 
ref. 
- -0.69 0.499 Retain in the 
model 
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Table A15. Adding Sex to the model  
 
Independent 
variable 
Regression 
coefficient 
% change t-test P-value Comment 
CD4 count 
≥200 
<200 
 
0.4831 
ref. 
12 0.69 0.504 Main predictor 
of interest 
Log duration of TB 
symptoms 
0.1154  - 0.15 0.881 Retain in the 
model 
Cavitary lung 
disease 
Present  
Absent  
 
-0.4919 
ref. 
- -0.64 0.535 Retain in the 
model 
Sex  
Female 
Male 
 
0.4113 
ref. 
- 0.54 0.598 Retain in the 
model  
 
 
 
Table A16. Adding Age to the model 
 
Independent variable Regression 
coefficient 
% change t-test P-value Comment 
CD4 count 
≥200 
<200 
 
0.5618 
ref. 
14 0.78 0.453 Main predictor 
of interest 
Log duration of TB 
symptoms 
0.0209  - 0.03 0.979 Retain in the 
model 
Cavitary lung disease 
Present  
Absent  
 
-0.7825 
ref. 
- -0.89 0.393 Retain in the 
model 
Sex  
Female 
Male 
 
0.3527 
ref. 
- 0.45 0.659 Retain in the 
model  
Age -0.0302 - -0.72 0.484 Retain in the 
model 
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Table A17. Adding TB Status to the model 
 
Independent variable Regression 
coefficient 
% change t-test P-value Comment 
CD4 count 
≥200 
<200 
 
0.4598 
ref. 
-22 0.67 0.515 Main predictor 
of interest 
Log duration of TB 
symptoms 
0.0826  - 0.11 0.912 Retain in the 
model 
Cavitary lung disease 
Present  
Absent  
 
-0.4518 
ref. 
- -0.53 0.608 Retain in the 
model 
Sex  
Female 
Male 
 
0.4443 
ref. 
- 0.60 0.558 Retain in the 
model  
Age 0.0059 - 0.13 0.898 Retain in the 
model 
TB Status  
Retreatment 
New 
 
-1.1253 
ref. 
- -1.16 0.135 Retain in the 
model 
 
 
Table A18.	Adding Smear Category to the model 
 
Independent variable Regression 
coefficient 
% change t-test P-value Comment 
CD4 count 
≥200 
<200 
 
0.1114 
ref. 
-313 0.12 0.909 Main predictor 
of interest 
Log duration of TB 
symptoms 
-0.1406  - -0.16 0.876 Retain in the 
model 
Cavitary lung disease 
Present  
Absent  
 
-0.3780 
ref. 
- -0.41 0.694 Retain in the 
model 
Sex  
Female 
Male 
 
0.1326 
ref. 
- 0.14 0.889 Retain in the 
model  
Age -0.0048 - -0.09 0.928 Retain in the 
model 
TB Status  
Retreatment 
New 
 
-0.9111 
ref. 
- -1.08 0.307 Retain in the 
model 
Smear category  
0/1+/2+ 
3+ 
4+ 
 
ref. 
0.6629 
1.0765 
- - 
0.43 
0.65 
0.678 
0.532 
Retain in the 
model  
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Table A19. Adding TB Treatment Duration to the model  
 
Independent variable Regression 
coefficient 
% change t-test P-value Comment 
CD4 count 
≥200 
<200 
 
0.1114 
ref. 
-313 0.12 0.909 Main predictor 
of interest 
Log duration of TB 
symptoms 
-0.1406  - -0.16 0.876 Retain in the 
model 
Cavitary lung disease 
Present  
Absent  
 
-0.3780 
ref. 
- -0.41 0.694 Retain in the 
model 
Sex  
Female 
Male 
 
0.1326 
ref. 
- 0.14 0.889 Retain in the 
model  
Age -0.0048 - -0.09 0.928 Retain in the 
model 
TB Status  
Retreatment 
New 
 
-0.9111 
ref. 
- -1.08 0.307 Retain in the 
model 
Smear category  
0/1+/2+ 
3+ 
4+ 
 
ref. 
0.6629 
1.0765 
- - 
0.43 
0.65 
0.678 
0.532 
Retain in the 
model  
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Presentations and publications 
 
-Poster presentation at MMS  
11/2010 ACP poster presentation for chapter meeting; Rhinoscleroma A forgotten 
infection –A Case report. Osman S, Alarcon I, Fliesher J.  
 
-Kelesidis T, Osman S, Tsiodras S. Emphysematous cystitis in the absence of 
known risk factors: an unusual clinical entity. South Med J. 2009 Sep; 102(9): 
942-6. 
 
-Kelesidis T, Osman S, Trayner E, Worthington M, Celli B. Tracheobronchitis 
caused by MRSA as a cause of chronic wheezing in non-ventilated adult with 
Tracheomalacia Respiration 2010;80(2):148-56. Epub 2009 Dec 30. 
 
-Kelesidis T, Osman S, Dinerman H. An unusual foreign body as a cause of 
chronic sinusitis J Med Case Reports. 2010 May 26; 4:157 
 
 
Regional Presentations 
 
-06/2015 CREST fellows research presentation 
Presented to professors of epidemiology, biostatistician, world known TB 
epidemiologists, professors of medicine and other research fellows preliminary 
results of my findings of tuberculosis transmission in HIV infected individuals 
 
-11/2014:Review over site committee                                                                                   
Presented to world wide known TB experts from the school of public health, 
infectious disease department project on the effect of HIV1 infection on TB 
infectivity.  
 
-6/2014:Effect of climate change on infectious disease                                                  
Journal club presentation on the state of the art on expected effect of global 
warming on infectious disease epidemiology and transmission. Mentored by Dr 
Jean-Van Seventer with a known expertise in the area of climate change. 
Audience is infectious disease attendings, Pediatrics infectious disease attendings, 
Internal medicine residents, Infectious disease fellows and BU medical student on 
ID rotation.  
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-10/2013: Malnutrition and role that gut Microbiota.                                                     
A journal club presentation about the role that gut microbiota plays on 
malnutrition and a place for antibiotics use in malnourished children in Malawi.  
Audience is infectious disease attendings, Pediatrics ID attnedings, GI fellows, ID 
fellows, ID pharmacists, Medical students and medical residents.   
                     
-10/2013:Empiric treatment for mycobacterial infections in SCT 
Case presentation highlighting the importance of thinking outside the box when 
treating critically ill patients with recent receipt of stem cell transplant.  
 
-9/2013:Significance of persistent high levels of serum Cryptococcus antigen   
Case presentations highlighting the significance of high Cryptococcus antigen in 
non-HIV patients with pulmonary symptoms despite several rounds of appropriate 
antifungal therapy. Case also underscored the importance of drug levels 
monitoring and susceptibility testing when feasible.  
 
 
Skills - Fluent in both English and Arabic.  
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